TY - JOUR
T1 - High efficacy of 1-week doxycycline- and amoxicillin-based quadruple regimen in a culture-guided, third-line treatment approach for Helicobacter pylori infection
AU - Cammarota, Giovanni
AU - Martino, Antonio
AU - Pirozzi, G
AU - Cianci, Rossella
AU - Branca, Giovanna
AU - Nista, Ec
AU - Cazzato, A
AU - Cannizzaro, O
AU - Miele, Luca
AU - Grieco, Antonio
AU - Gasbarrini, Antonio
AU - Gasbarrini, Giovanni Battista
PY - 2004
Y1 - 2004
N2 - BACKGROUND: Helicobacter pylori infection may persist after both first- and second-line current treatments.
AIM: To assess the efficacy of a third-line, culture-guided treatment approach for the eradication of H. pylori.
METHODS: Patterns of resistance were analysed in H. pylori isolates from 94 consecutive patients in whom H. pylori infection had persisted after two eradication attempts. Using the epsilometer test, susceptibility analysis was performed for amoxicillin, clarithromycin, metronidazole, tetracycline and levofloxacin. Patients were then treated with a culture-guided, third-line regimen: 89 patients with a 1-week quadruple regimen including omeprazole, bismuth, doxycycline and amoxicillin, and five patients with a 1-week triple regimen containing omeprazole, amoxicillin and levofloxacin or clarithromycin.
RESULTS: Ninety-four subjects (100%) were resistant to metronidazole, 89 (95%) to clarithromycin, 29 (31%) to levofloxacin and five (5%) to tetracycline. No resistance to amoxicillin was found in any patient. Overall, H. pylori eradication was obtained in 90% of subjects. The quadruple regimen was effective in 81 patients (92% by per protocol and 91% by intention-to-treat analysis). Four patients (80%, both per protocol and intention-to-treat analysis) were H. pylori-negative after the triple regimen.
CONCLUSIONS: A culture-guided, third-line therapeutic approach is effective for the eradication of H. pylori. Furthermore, the 1-week doxycycline- and amoxicillin-based quadruple regimen is a good third-line 'rescue' treatment option.
AB - BACKGROUND: Helicobacter pylori infection may persist after both first- and second-line current treatments.
AIM: To assess the efficacy of a third-line, culture-guided treatment approach for the eradication of H. pylori.
METHODS: Patterns of resistance were analysed in H. pylori isolates from 94 consecutive patients in whom H. pylori infection had persisted after two eradication attempts. Using the epsilometer test, susceptibility analysis was performed for amoxicillin, clarithromycin, metronidazole, tetracycline and levofloxacin. Patients were then treated with a culture-guided, third-line regimen: 89 patients with a 1-week quadruple regimen including omeprazole, bismuth, doxycycline and amoxicillin, and five patients with a 1-week triple regimen containing omeprazole, amoxicillin and levofloxacin or clarithromycin.
RESULTS: Ninety-four subjects (100%) were resistant to metronidazole, 89 (95%) to clarithromycin, 29 (31%) to levofloxacin and five (5%) to tetracycline. No resistance to amoxicillin was found in any patient. Overall, H. pylori eradication was obtained in 90% of subjects. The quadruple regimen was effective in 81 patients (92% by per protocol and 91% by intention-to-treat analysis). Four patients (80%, both per protocol and intention-to-treat analysis) were H. pylori-negative after the triple regimen.
CONCLUSIONS: A culture-guided, third-line therapeutic approach is effective for the eradication of H. pylori. Furthermore, the 1-week doxycycline- and amoxicillin-based quadruple regimen is a good third-line 'rescue' treatment option.
KW - Amoxicillin
KW - Anti-Bacterial Agents
KW - Doxycycline
KW - Drug Resistance, Bacterial
KW - Drug Therapy, Combination
KW - Helicobacter Infections
KW - Helicobacter pylori
KW - Amoxicillin
KW - Anti-Bacterial Agents
KW - Doxycycline
KW - Drug Resistance, Bacterial
KW - Drug Therapy, Combination
KW - Helicobacter Infections
KW - Helicobacter pylori
UR - http://hdl.handle.net/10807/20959
U2 - 10.1111/j.1365-2036.2004.01910.x
DO - 10.1111/j.1365-2036.2004.01910.x
M3 - Article
SN - 0269-2813
VL - 19
SP - 789
EP - 795
JO - ALIMENTARY PHARMACOLOGY & THERAPEUTICS
JF - ALIMENTARY PHARMACOLOGY & THERAPEUTICS
ER -